THERAPEUTICS
Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke
| The first 150 words of the full text of this article appear below. |
R L Sacco
Dr R L Sacco, University of Miami, Miami, FL, USA; rsacco@med.miami.edu
STUDY DESIGN
randomised controlled trial with 2 x 2 factorial design (Prevention Regimen for Effectively Avoiding Second Strokes [PRoFESS]). ClinicalTrials.gov NCT00153062 [ClinicalTrials.gov] .
concealed.*
{blinded (patients, clinicians, data collectors, outcome assessors, safety committee, and data analysts)}
.*
STUDY QUESTION
695 centres in 35 countries worldwide.
20 332 patients
50 years of age (mean age 66 y, 64% men) who had had an ischaemic stroke in the previous 120 days and were clinically and neurologically stable.
aspirin, 25 mg, plus extended-release dipyridamole (ERDP), 200 mg, twice daily (n = 10 181) or clopidogrel, 75 mg, once daily (n = 10 151). Patients were also randomised to telmisartan or placebo (see Yusuf abstract).
recurrent stroke of any type, a composite end point (stroke, myocardial infarction, or death from vascular causes), and major bleeding. The trial had >82% power to reject the inferiority null
University of South Florida, Tampa, Florida, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
